A series of new compounds, carbocyclic oxetanocins, have been synthesized and their
Acyclovir (ACV) is the most successful antiviral agent that has been licenced for the treatment of herpes simplex virus (HSV) infections, and has proved beyond all doubt that antiviral therapy with minimal toxicity is an achievable goal. But this agent is not so active against HSVtype 2 (HSV-2) as against HSV type 1 (HSV-1)1>2), and has shown little efficacy in the treatment of human cytomegalovirus (HCMV) infections1~4). Ganciclovir (DHPG), a potent inhibitor against HCMV in vitro, is currently undergoing clinical trials for the treatment of HCMV infections in bone marrow transplant recipients and in patients with aquired immunodeficiency syndrome (AIDS)5~8). Although ganciclovir has demonstrated significant antiviral activity against HCMVin these patients, the therapeutic efficacy is limited by its toxicity, principally ganciclovir-induced myelosuppression9~1 1}. Therefore it is necessary to keep on searching more selective and potent agents against these pathogens. Recently we have reported that oxetanocin G (OXT-G), a novel nucleoside having an oxetanocyl-7V-glycoside linkage, has a potent and selective antiviral activity against HCMV in vitro12). OXT-Gwas also highly effective against systemic HSV-2and murine CMVinfections in mice13). As part of our antiviral chemotherapy program, we had an interest in carbocyclic analogs of oxetanocins. In the present study, we investigated the effect of these compoundsagainst HSVand HCMV in vitro.
Materials and Methods

Chemicals
OXT-G were synthesized as described previously14). NNU-018 and -019 were synthesized from ( + )-(l a,3^)-3-(^r^-butyldiphenylsilyloxymethyl)cyclobutanel-yl methansulfonate with adenine or 2-amino-6-(2-methoxyethoxy)purine, followed by deprotection. NNU-01 1 and -01 3 were synthesized from ( + )-(la,2j5,4a)-2-(/er^-butyldiphenylsilyloxymethyl)-5-oxa-bicyclo[2.
1.0]pentane with adenine or 2-amino-6-(2-methoxyethoxy)purine, followed by deprotection.
Procedures for chemical synthesis of these four compounds will be described in detail elsewhere. NNU-022 and -023 were synthesized from 
Cells and Viruses
Vero cells, a line of African green monkeykidney cells, and human embryonic fibroblasts (HEF) were used in this study and were grown in Eagle's minimumessential medium(MEM)supplemented with 7% calf serum (CS) and 10% fetal calf serum (FCS), respectively.
HSV-1 strain HF, HSV-2 strain 186 (wild type [TK+] and thymidine kinase deficient [TK~]), and HCMVstrain AD169 were propagated in HEF cell monolayers as described previously16'17).
Plaque Reduction Assays Con fluent monolayers of Vero or HEF cells in plastic dishes (diameter, 35mm) were infected with 100 to 150 plaque forming units (PFU) ofHSV or HCMV. After a 1-hour adsorption period at 37°C, the cultures were overlaid with 2ml of 0.5% agarose in MEMcontaining 3% FCSand various concentrations of drugs. The cultures infected with HSVor HCMVwere fixed and stained at 1 or 2 and 9 or 10 days after infection, respectively. In the case of HCMV-infectedcultures, the second agarose overlay containing appropriate concentrations of drugs wasadded5 days after infection. Plaque numberswere counted by using a dissecting microscope at x 20 magnification.
Yield Reduction Assays Monolayers of Vero or HEFcells were infected with HSV-2 or HCMV at a multiplicity of about 10 PFUper cell and treated with various concentrations of drugs after a 1-hour virus adsorption period at 37°C. HSV-2 and HCMV were harvested 24 hours and 5 days postinfection, respectively. After freeze-thawing followed by low speed centrifugation, the supernatant was assayed for virus infectivity.
Results
Antiviral Activities of Carbocyclic Oxetanocins The antiviral activities of carbocyclic oxetanocins were measured by the plaque reduction assays and Vero or HEF cells were infected with either HSV-2 or HCMVat a multiplicity of infection of approximately 10 PFU/cell, as described in Materials and Methods. The titers were the average of triplicate samples.
were expressed in terms of median effective concentrations (EC50) which were defined as the drug concentrations that reduced viral replication to 50%. The results are shown in Table 1 . Among six compounds tested, NNU-023, carbocyclic OXT-G,was found to have the most potent anti-herpetic activity; the EC50 of this compound against HSV-2 and HCMVwere approximately 0.04 and 0.40 /xg/ml, respectively.
The EC50 value of NNU-023 against HSV-2 was significantly lower than those of ACVand DHPG, while the EC50 value of this compound against HCMV was comparable to that of DHPG18~20). Similar results were obtained in yield reduction assays where cells were infected with HSV-2and HCMVat a relatively high multiplicity (10 PFU/cell) (Fig. 2) , namely NNU-023 was much more active against HSV-2 than ACVand DHPG.
Effect of Carbocyclic OXT-G against Thymidine Kinase Deficient (TK~) Mutant of HSV-2 Wecompared the activity of NNU-023with those ofOXT-G, ACVand DHPGagainst wild-type and TK~HSV-2. As reported previously12),
OXT-G exhibited equal potencies against TK+ and TKH SV-2, while the antiviral activity of ACVand DHPGwas strikingly weakened by the lack of 1857 HSV-induced TK. Although carbocyclic OXT-G was still most active among four compoundsagainst TK" HSV-2, the EC50value increased about 35-fold compared with that against TK+HSV-2 ( Table 2) .
Reversal of Anti-herpetic Activity of NNU-023 by Exogenous Nucleosides
The effect of the addition of exogenous nucleosides on the antiviral activity of NNU-023was investigated to characterize the modeof action of this compound. Con fluent monolayers of Vero cells were infected with about 100 PFUofHSV-2, and after a 1-hour virus adsorption period, cells were overlaid with 0.5% agarose containing NNU-023 and deoxyribonucleosides.
As shown in Table 3 , the antiviral activity of NNU-023 was partially reversed by the addition of 100-fold excess deoxyguanosine (dG). The addition of four deoxynucleosides (4dN) all together was much more effective in reversing the antiviral effect of NNU-023than that of dG alone. However, even 100-fold excess of 4dN did not induce complete reversion of antiviral effect of carbocyclic OXT-G. Discussion NNU-023 (carbocyclic OXT-G) was most potent against HSV-2 and HCMVamong carbocyclic oxetanocins tested; the EC50 of HSV-2 and HCMVwas 0.04 and 0.40//g/ml, respectively. The activity of this compound against HSV-2 was significantly more potent than those of ACVand DHPG.However, the inhibitory concentration of the agent for the growth of Vero cells was lower than those of ACVand DHPG; NNU-023 inhibited the growth of Vero cells by 50% at the concentration of about 5 /ig/ml (data not shown) and then the selectivity index was 125. While OXT-Gexhibited equal potencies against TK+ and TK" HSV-2, carbocyclic OXT-Gwas about 35-fold more active against TK+HSV-2than a TK" mutant. This observation suggests that carbocyclic OXT-G,unlike OXT-G,is a good substrate for HSV-2-induced TK. Since carbocyclic OXT-G still showed the high activity against TK" HSV-2, this nucleoside analog must be well phosphorylated by a nucleoside kinase of Vero cells too. Antiviral activity of NNU-023was only partially reversed even with 100-fold excess of dG, and the addition of 4dN was shown to be much more effective in reversing antiviral activity than that of dG alone. DEC. 1989 These results suggest that the antiviral effect of carbocyclic OXT-G can not be solely due to its ability to act as a dG analog. On the other hand, the antiviral activity of OXT-Gcan be reversed more effectively by the addition of dG alone (unpublished observation). It appears that the mode of action of carbocyclic OXT-Gis different from that of OXT-G. In addition to these observations, our preliminary in vivo studies have shown that the administration of NNU-023at a dose of 5 mg/kg/day is highly effective in reducing the mortality rate of HSV-2-infected mice. Whenevaluated under the same conditions, on the other hand, ACVhad little or no effect on the mortality rate even at the dose of 50mg/kg/day13). We also found that NNU-023did not induce any overt signs of toxicity in mice, which received intraperitoneally the drug at a dose of20mg/kg/day for 10 days. We thus conclude that NNU-023is a compound worth further investigation.
